Dr. Kelly on Selecting Therapy for Patients with CRPC

William Kevin Kelly, DO
Published: Wednesday, Nov 27, 2013

William Kevin Kelly, DO, professor of medical oncology and urology, Thomas Jefferson University, discusses the possibility of preselecting which castration-resistant prostate cancer (CRPC) patients will be sensitive to chemotherapy or hormone therapy.

Kelly says there are a number of small trials that are looking at androgen levels by using sensitive assays and spectroscopy to determine if there are any residual androgens. Researchers are also looking at the cellular level, to see if the androgen receptor pathway is active by looking at the retinoblastoma gene, which can determine if patients will be sensitive to chemotherapy or other agents.

These tools can be integrated into clinical trials, Kelly says.

William Kevin Kelly, DO, professor of medical oncology and urology, Thomas Jefferson University, discusses the possibility of preselecting which castration-resistant prostate cancer (CRPC) patients will be sensitive to chemotherapy or hormone therapy.

Kelly says there are a number of small trials that are looking at androgen levels by using sensitive assays and spectroscopy to determine if there are any residual androgens. Researchers are also looking at the cellular level, to see if the androgen receptor pathway is active by looking at the retinoblastoma gene, which can determine if patients will be sensitive to chemotherapy or other agents.

These tools can be integrated into clinical trials, Kelly says.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x